Growth Metrics

Pfizer (PFE) Operating Margin (2016 - 2025)

Historic Operating Margin for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to 38.81%.

  • Pfizer's Operating Margin rose 33100.0% to 38.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 50.55%, marking a year-over-year increase of 507000.0%. This contributed to the annual value of 27.98% for FY2024, which is 175600.0% up from last year.
  • Latest data reveals that Pfizer reported Operating Margin of 38.81% as of Q3 2025, which was up 33100.0% from 34.48% recorded in Q2 2025.
  • In the past 5 years, Pfizer's Operating Margin ranged from a high of 47.01% in Q3 2022 and a low of 410.16% during Q4 2023
  • Its 5-year average for Operating Margin is 22.31%, with a median of 35.6% in 2021.
  • As far as peak fluctuations go, Pfizer's Operating Margin plummeted by -2380700bps in 2023, and later skyrocketed by 2331600bps in 2024.
  • Over the past 5 years, Pfizer's Operating Margin (Quarter) stood at 32.77% in 2021, then skyrocketed by 39bps to 45.45% in 2022, then plummeted by -1002bps to 410.16% in 2023, then skyrocketed by 109bps to 35.5% in 2024, then rose by 9bps to 38.81% in 2025.
  • Its last three reported values are 38.81% in Q3 2025, 34.48% for Q2 2025, and 36.15% during Q1 2025.